STOCK TITAN

Aptevo Therapeutics Inc - APVO STOCK NEWS

Welcome to our dedicated news page for Aptevo Therapeutics (Ticker: APVO), a resource for investors and traders seeking the latest updates and insights on Aptevo Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aptevo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aptevo Therapeutics's position in the market.

Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) closes a $4.6 million public offering, selling 3,400,000 shares of common stock and warrants to purchase 6,800,000 shares at $1.35 per share. The company plans to use the proceeds for clinical development, working capital, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.92%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) announces a public offering of 3.4 million shares of common stock and warrants to purchase 6.8 million shares at $1.35 per share. Each share comes with two Common Warrants, with an exercise price of $1.35 per share, expiring in five years.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-60.08%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (APVO) announces positive advancements in clinical and preclinical programs, including a breast cancer patient transitioning to a higher dose level in the ALG.APV-527 trial, APVO436 Phase 1b/2 trial initiation expected in 1H 2024, and engagement of Prometrika as a partner for dose optimization trial. APVO711 shows promise in inducing tumor killing properties in preclinical studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-26.38%
Tags
none
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) is participating in The Springtime Event, a Bio-Europe conference in Barcelona, Spain. The event aims to foster relationships within the biotechnology and biopharmaceutical industries, with key representatives from Aptevo attending.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.12%
Tags
none
-
Rhea-AI Summary
Alligator Bioscience and Aptevo Therapeutics announce positive interim data for ALG.APV-527 in Phase 1 trial for solid tumors expressing tumor antigen 5T4. The trial shows favorable drug exposure, biological activity, and signs of clinical activity in heavily pretreated patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.12%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. announces 1H24 plan for the development of lead candidate APVO436 for frontline acute myeloid leukemia. Interim results expected late 2H24. Phase 1 trial for APV-527 for multiple solid tumors continues enrollment, with interim results expected 1H24. Financial results for 2023 and business update provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.55%
Tags
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) announced a 1-for-44 reverse stock split to regain Nasdaq compliance, reducing outstanding shares from 23.5 million to approximately 0.53 million. The split aims to maintain a minimum bid price of $1.00 per share and will not change the trading symbol 'APVO'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.72%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ: APVO) reported financial results and provided a business update, including progress in the ALG.APV-527 Phase 1 Trial for the Treatment of Multiple Solid Tumors, planning for APVO436 Phase 2 Trial Initiation, and extended cash runway with $7 million in funding and potential for additional $9.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.7%
Tags
-
Rhea-AI Summary
Aptevo Therapeutics Inc. (NASDAQ:APVO) will present at the Bio-Europe conference in Munich, Germany from November 6-8, 2023. The presentation will focus on the company's pipeline of clinical and pre-clinical bispecific drug candidates for treating solid and hematologic malignancies. Michelle Nelson, Ph.D., Director of Immunobiology, will be the presenter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.85%
Tags
conferences
Rhea-AI Summary
Aptevo Therapeutics Inc. reported positive duration of remission data for its lead clinical candidate, APVO436, and announced the initiation of Phase 2 trials for the treatment of AML. The company also completed a $5 million equity raise, extending its cash runway into 3Q24.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.6%
Tags
Aptevo Therapeutics Inc

Nasdaq:APVO

APVO Rankings

APVO Stock Data

1.23M
532.87k
0.1%
1.09%
5.09%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Seattle

About APVO

aptevo therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. we leverage the innovative adaptir™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients. based in seattle, washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. as a result, aptevo has been able to attract some of the most innovative minds in the field. many of our team members have notable experience with other pioneering biotech companies including trubion, zymogenetics, immunex, dendreon, and vlst. at aptevo therapeutics, our core values of ownership and collaboration—combined with a history of innovation, dedication, and development—are positioning aptevo therapeutics to develop the science of what’s next in biotechnology.